---
title: Emetic risk classification and evaluation of the emetogenicity of antineoplastic
  agents-updated MASCC/ESMO consensus recommendation
date: '2023-12-21'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38129530/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231222170724&v=2.18.0
source: heidelberg[Affiliation]
description: 'CONCLUSION: The MASCC/ESMO Expert Panel acknowledges the limitations
  of our efforts to classify the emetic potential of anticancer agents, especially
  the imprecision associated with oral agents. However, we have attempted to provide
  a reasonable approximation of the emetic risk associated with new antineoplastic
  agents by searching the available literature and reviewing other available international
  antiemetic ...'
disable_comments: true
---
CONCLUSION: The MASCC/ESMO Expert Panel acknowledges the limitations of our efforts to classify the emetic potential of anticancer agents, especially the imprecision associated with oral agents. However, we have attempted to provide a reasonable approximation of the emetic risk associated with new antineoplastic agents by searching the available literature and reviewing other available international antiemetic ...